期刊文献+

乙型肝炎病毒DNA聚合酶TP257抗α-干扰素机制初步探讨

Preliminary investigation of the anti-IFN-α effect of the TP257 protein of hepatitis B virus DNA polymerase
原文传递
导出
摘要 目的筛选与乙型肝炎病毒DNA聚合酶N端257个氨基酸(TP257)相结合的抗α-干扰素(IFN-α)相关性肝细胞蛋白,初步探讨TP257抗IFN-α作用机制。方法构建TP257腺病毒穿梭载体pShuttle-IRES-hrGFP-TP257,并与腺病毒骨架载体pADEasy-1重组,以293A细胞包装重组腺病毒。用重组腺病毒感染Huh7细胞并以IFN-α诱导,收获细胞蛋白,Western blot验证TP257蛋白在细胞中的表达。细胞蛋白进行免疫沉淀,SDS-PAGE分离后通过质谱鉴定差异蛋白。结果构建的重组腺病毒AD-TP257能有效感染Huh7细胞并大量表达TP257蛋白。Huh7细胞感染AD-TP257后以IFN-α处理,并通过免疫沉淀筛选到4种差异蛋白,其中3种经肽质量指纹图谱鉴定分别为热休克蛋白60、组蛋白HIST1H2BC和肌凝蛋白调节轻链12A。结论 TP257抗IFN-α效应可能与它和特定肝细胞蛋白结合并相互作用有关。 Objective To screen for the cellular proteins that combine with the TP257 protein of HBV DNA polymerase and preliminarily investigate the mechanism of the anti-IFN-α effects of TP257. Methods The adenovirus shuttle vector pShuttle-IRES-hrGFP-TP257 was constructed and rccombined with adenovirus backbone vector pADEasy-1. The recombinant adenovirus particles were packaged and harvested in 293A cells. Huh7 cells were infected with recombinant adenoviral particles and treated with IFN-α . Expression of TP257 was verified by Western blotting, and cell proteins were subjected to immunoprecipitation. After separation by SDS-PAGE, the differentially precipitated proteins were identified by mass spectrometry. Results Recombinant adenovirus particles AD-TP257 were successfully generated and effectively infected Huh7 cells and also expressed the TP257 protein. After treatment of AD-TP257-infected Huh7 cells with IFN-α, four proteins were immunoprecipitated. Three were identified by MALDI-TOF-MS as a 60 ku heat shock protein, HIST1H2BC protein, and myosin regulatory light chain 12A, respectively. Conclusion Anti-IFN-α effects of TP257 may result from its binding to and interaction with certain cellular proteins.
出处 《中国病原生物学杂志》 CSCD 2011年第4期241-245,共5页 Journal of Pathogen Biology
基金 国家自然科学基金项目(No.30840069) 福建省高校科技创新团队培育计划基金项目(No.FMU-RT001) 福建省卫生教育联合攻关计划项目(No.WKJ2008-2-056)
关键词 乙型肝炎病毒 DNA聚合酶 Α-干扰素 免疫沉淀 Hepatitis B Virus DNA polymerase interferon-α immunoprecipitation
  • 相关文献

参考文献16

  • 1Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response [J]. Annu Rev Im- munol, 2001, 9: 65.
  • 2Niederau K, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon-alpha for chronic hepatitis B [J]. N Eng J Med, 1996, 334: 1422-7.
  • 3Van Zonneveld M, Honkoop P, Hansen BE, et al. Long-term follow-up of alpha-interferon treatment of patients with ehronie hepatitis B [J]. Hepatology, 2004, 39(3): 804-10.
  • 4Foster GR, Ackrill AM, Goldin RD, et al. Expression of Termi- nal protein region of hepatitis B virus inhibits cellular responses to interferons alpha and gamma and double-stranded RNA [J]. Proc Natl Acad Sci USA, 1991, 88: 2888-92.
  • 5Foster GR, Goldin RD, Hay A, et al. Expression of the terminal protein of hepatitis B virus is associated with failure to interferon therapy[J]. LiverDise, 1993, 5:757-62.
  • 6Poch O, Sauvaget I, Delarue M, et al. Identification of four con- served motifs among the RNA dependent polymerse encoding ele- ments [J]. EMBO J, 1989, 8(12): 3867-74.
  • 7王林,柏世玉,陈婉南,李晖,林建银,林旭.乙型肝炎病毒DNA聚合酶末端蛋白抗α-干扰素功能区域分析[J].中华微生物学和免疫学杂志,2007,27(6):540-545. 被引量:5
  • 8Sen GC, Sarkar SN. Viruses and interferon[J]. Curr Top Micro- biol Immunol, 2007, 316: 233-50.
  • 9Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors [J]. Hepatolo- gy, 1989, 10(5): 761-3.
  • 10Park SG, Jung G. Human hepatitis B virus polymerase interacts with the molecular chaperonin Hsp60 [J]. J Virol, 2001, 75: 6962-8.

二级参考文献18

  • 1Samuel CE. Antiviral actions of intexferons. Clin Microbiol Rev, 2001, 14(4) : 778-809.
  • 2Wong DK, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon in patients with hepatitis B e antigen positive chronic hepatitis B: a meta-analysis. Ann Intern Med, 1993, 119(4): 312-323.
  • 3Hoofnagle JH, di Bisceglie AM. The treatment of chronic viral hepatitis. N Eng J Med, 1997, 336(5) : 347-356.
  • 4Niederau C, Heintges T, Lange S, et al. long-term follow-up of HBeAg-positive patients treated with interferon-alpha for chronic hepatitis B. N Eng J Med, 1996, 334(22) : 1422-1427.
  • 5Foster GR, Ackrill AM, Goldin RD, et al. Expression of the terminal protein region of hepatitis B virus inhibits cellular responses to interferons alpha and gamma and double-stranded RNA. Proc Natl Acad Sci. U S A, 1991, 88(7): 2888-2892.
  • 6Porter AC, Chemajovsky Y, Dale TC, et al. Interferon response element of the human gene 6-16. EMBO J, 1988, 7(1) : 85-92.
  • 7Perrillo RP. Current treatment of chronic hepatitis B : benefits and limitations. Semin Liver Dis, 2005, 25(Suppl 1): 20-28.
  • 8Brunetto MR, Oliveri FC, Coco B, et al. Outcome of anti-Hbe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol, 2002, 36(2): 263-370.
  • 9Suzuki F, Tsubota A, Akuta N, et al. Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy. J Gastroenterol, 2002, 37 ( 11 ) : 922- 927.
  • 10Beook MG, Karayiannis P, Thomas HC, et al. Which pationts with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology, 1989, 10 (5) : 761-763.

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部